« Return to News | Study Conduct | CROs/Service Providers

Quintiles Plans Phase I Unit in India

Wednesday, January 28, 2009 08:00 AM

Contract research organization (CRO) Quintiles is partnering with Apollo Hospitals Group in India to open a phase I clinical trial unit in Hyderabad, India.

Scheduled to open in early 2010 on Apollo’s Hyderabad hospital campus, the new unit will have approximately 50 beds with the capacity to expand to 100 beds, if necessary. Quintiles and Apollo anticipate their combined investment for the new unit will be $6 million.

The new unit, which will evaluate compounds developed both within and outside of India, will be Quintiles’ fifth location in India, but the first offering phase I services.

“Phase I development in both healthy volunteers and patients is at the forefront of our quest for new and better medicines. Phase I can help expedite the development process and ensure that only those compounds with most promise are further evaluated,” said Quintiles’ senior vice president, global phase I, Eddie Caffrey, in a company statement.

Quintiles’ other phase I facilities are located in England, Kansas and Sweden.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.